Back to search results
NCT05325242

Elbow Artery Embolization for Tennis Elbow

Active, Not Recruiting
NAAges 18+InterventionalTreatment
Siddharth Padia, MD
~13 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:Embozene particles

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assess the efficacy of EAE in treating pain measured as percentage of subjects with a greater than 50% decrease in QuickDASH (Disabilities of the Arm, Shoulder, and Hand) score at 12 months.
Measured over 12 months

Conditions

Lateral Epicondylitis, Unspecified Elbow

Explore related trials

Lateral Epicondylitis

NCT05325242

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California, Los Angeles

    Los Angeles, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Siddharth Padia, M.D. · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Diagnosis of lateral epicondylitis based on history and physical exam
Ability to provide informed consent
Life expectancy greater than 12 months
Moderate-severe lateral elbow pain as determined by visual analog scale \> 4 (based on average severity during physical activity)
Resistant/failed conservative treatment (e.g. NSAIDS/physical therapy/steroid joint injection) for at least 6 months.

Exclusion

Mild elbow pain as determined by visual analog scale \< 4
Chronic renal insufficiency (serum creatinine \>2 mg/dL)
Allergy to iodinated contrast agents that is not responsive to steroid management
Active Infection or malignancy
Prior elbow surgery in the subject elbow
Uncorrectable bleeding diathesis

What this trial measures

  • Assess the efficacy of EAE in treating pain measured as percentage of subjects with a greater than 50% decrease in QuickDASH (Disabilities of the Arm, Shoulder, and Hand) score at 12 months.12 months

    Changes in QuickDASH (Disabilities of the Arm, Shoulder, and Hand) score as a measure of efficacy.